FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3096498467> ?p ?o ?g. }

• W3096498467 endingPage "31" @default.
• W3096498467 startingPage "30" @default.
• W3096498467 abstract "Introduction. Mutations in genes encoding the metabolic enzymes isocitrate dehydrogenase (IDH) 1 and 2 are found in 10-20% of patients with acute myeloid leukemia (AML). Recently, IDH inhibitors have shown good clinical response in patient's refractory to standard treatments, providing evidence for a new treatment paradigm. Comprehensive real-world studies are needed to explore genotype-to-phenotype correlations and prognosis of IDH mutated AML, which may influence targeted treatment strategies. Patients. From a retrospective, European, real-word population (ClinicalTrials.gov Identifier: NCT04369287) we studied 477 IDH mutated patients and 954 IDH wild type patients matched for age, sex and type of treatment with a 1:2 ratio. Results. Median age of IDH mutated patients was 67 years; IDH1 mutations were found in 202 patients (89% carried R132 mutation), while IDH2 mutations were found in 275 cases (51% and 28% carried R140 and R172 mutations, respectively). At diagnosis, IDH mutated patients had lower neutrophil and higher platelet count and higher percentage of marrow blasts (P&lt;0.001). IDH mutations were more frequently observed in de novo AML vs. AML from previous myeloid malignancy (P=0.043). Considering cytogenetic risk according to ELN criteria, the great majority of IDH1 and IDH2 mutated patients had an intermediate cytogenetic risk (84% and 86%, respectively, P&lt;.001, most of them showing a normal karyotype). Considering IDH1 vs. IDH2 mutated population, deletion of chromosome 7 was more frequently reported in IDH2 mutated patients (P=.001). We then analysed the most common co-mutational patterns in IDH mutated patients. A total of 53% of IDH1 mutated patients carried NPM1 mutations (without FLT3 mutations), while the majority of IDH2 mutated patients had wild type NPM1 gene (P&lt;.001). IDH2 mutated patients more frequently presented with co-mutation in FLT3 gene (P&lt;.001); among IDH2/FLT3 co-mutated patients, the great majority of cases carried the R140 mutation (P&lt;.001). ASXL1 mutations were also more frequently associated with IDH2 mutations (P=.029). Most patients with CEBPA biallelic mutations carried IDH1 or 2 mutations (66%, P=.01), while core binding factor translocations, and mutations in TP53 and RUNX1 were rarely associated with IDH1 or 2 mutations. Median overall survival from diagnosis (OS) was 14 months for IDH1 mutated patients, 23 for IDH2 mutated patients and 19 for IDH wild type patients (P&lt;.001, figure 1); the independent negative effect on OS for IDH1 mutations was confirmed in a multivariable analysis on the whole study population including age, sex, ELN risk group, and type of treatment as covariates (HR was 1.65 vs. wild type population and 1.36 vs. IDH2 mutated patients, P&lt;.001), as well as in a specific analysis focused on patients belonging to intermediate ELN risk category (HR 1.75 vs. wild type population, P&lt;.001). Focusing on different mutational hotspots, survival analysis confirmed that IDH1 R132 mutation was associated with worse prognosis among IDH mutated patients (P&lt;.001). Moreover, we observed a reduced relapse-free survival (RFS) for both IDH1 and 2 mutated patients vs. wild type patients (P&lt;.001, figure 1). Multivariable analysis confirmed worse RFS for IDH1 and 2 patients vs. wild type patients (HR 3.8 and 1.4, respectively, P&lt;.001), as well as for IDH1 vs. IDH2 mutated patients (HR 1.5, P&lt;.001). IDH mutated patients receiving hypomethylating agents (n=211) had a lower response rate vs. wild type patients (56% vs. 36% of treatment failure, respectively, P=.04), while no significant different probability of response to intensive chemotherapy was noticed. In patients who received allogeneic transplantation (n=345), IDH1 mutated patients shower higher relapse rate vs. wild type and IDH2 mutated patients (53% vs. 34%, P&lt;.001). Conclusion. In a real world context, AML patients with IDH1 and 2 mutations have high marrow blasts percentage, frequently present normal karyotype and show specific co-mutational patterns with respect to NPM1, FLT3 and ASXL1 genes. IDH1 mutations were an independent predictor of unfavorable outcome with high rate of disease recurrence under currently available treatment options, and could be considered as an additional marker to improve personalized prognostic assessment within ELN risk groups. Dissection of prognosis of IDH mutated AML may influence targeted treatment strategies in clinical practice. Disclosures Voso: Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. Heibl:Takeda: Honoraria; AOP orphan: Consultancy, Honoraria, Research Funding; BMS/celgene: Consultancy, Honoraria, Research Funding; novartis: Consultancy, Honoraria. Metzeler:Astellas: Honoraria; Daiichi Sankyo: Honoraria; Otsuka Pharma: Consultancy; Pfizer: Consultancy; Jazz Pharmaceuticals: Consultancy; Novartis: Consultancy; Celgene: Consultancy, Honoraria, Research Funding. Thiede:AgenDix GmbH: Other: Co-owner and CEO. Fracchiolla:ABBVIE: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, accommodations, expenses; Gilead: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, accommodations, expenses, Speakers Bureau; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, accommodations, expenses, Speakers Bureau; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, accommodations, expenses, Speakers Bureau. Todisco:Jannsen, Abbvie, Jazz: Membership on an entity's Board of Directors or advisory committees. Passamonti:Novartis: Speakers Bureau; BMS: Speakers Bureau; Roche: Other: Support of parent study and funding of editorial support." @default.
• W3096498467 created "2020-11-09" @default.
• W3096498467 creator A5000942690 @default.
• W3096498467 creator A5006122560 @default.
• W3096498467 creator A5006887524 @default.
• W3096498467 creator A5007988543 @default.
• W3096498467 creator A5009381933 @default.
• W3096498467 creator A5012020159 @default.
• W3096498467 creator A5012932458 @default.
• W3096498467 creator A5016635620 @default.
• W3096498467 creator A5016773523 @default.
• W3096498467 creator A5017225753 @default.
• W3096498467 creator A5018098518 @default.
• W3096498467 creator A5021490305 @default.
• W3096498467 creator A5023947480 @default.
• W3096498467 creator A5025528565 @default.
• W3096498467 creator A5027358264 @default.
• W3096498467 creator A5028199476 @default.
• W3096498467 creator A5030071814 @default.
• W3096498467 creator A5030156947 @default.
• W3096498467 creator A5033227605 @default.
• W3096498467 creator A5037944783 @default.
• W3096498467 creator A5041966654 @default.
• W3096498467 creator A5043879976 @default.
• W3096498467 creator A5044088234 @default.
• W3096498467 creator A5046914814 @default.
• W3096498467 creator A5046965677 @default.
• W3096498467 creator A5047829491 @default.
• W3096498467 creator A5050727941 @default.
• W3096498467 creator A5052993212 @default.
• W3096498467 creator A5053254720 @default.
• W3096498467 creator A5053685451 @default.
• W3096498467 creator A5056151840 @default.
• W3096498467 creator A5063296742 @default.
• W3096498467 creator A5063417364 @default.
• W3096498467 creator A5063825892 @default.
• W3096498467 creator A5067177016 @default.
• W3096498467 creator A5069133916 @default.
• W3096498467 creator A5075950572 @default.
• W3096498467 creator A5076095056 @default.
• W3096498467 creator A5082287365 @default.
• W3096498467 creator A5083230780 @default.
• W3096498467 creator A5086066293 @default.
• W3096498467 creator A5089534178 @default.
• W3096498467 creator A5090912200 @default.
• W3096498467 date "2020-11-05" @default.
• W3096498467 modified "2023-10-06" @default.
• W3096498467 title "Acute Myeloid Leukemia with Isocitrate Dehydrogenases (IDH) 1 and 2 Mutations. a Real-World Study from the European IDH Research Group" @default.
• W3096498467 doi "https://doi.org/10.1182/blood-2020-140494" @default.
• W3096498467 hasPublicationYear "2020" @default.
• W3096498467 type Work @default.
• W3096498467 sameAs 3096498467 @default.
• W3096498467 citedByCount "0" @default.
• W3096498467 crossrefType "journal-article" @default.
• W3096498467 hasAuthorship W3096498467A5000942690 @default.
• W3096498467 hasAuthorship W3096498467A5006122560 @default.
• W3096498467 hasAuthorship W3096498467A5006887524 @default.
• W3096498467 hasAuthorship W3096498467A5007988543 @default.
• W3096498467 hasAuthorship W3096498467A5009381933 @default.
• W3096498467 hasAuthorship W3096498467A5012020159 @default.
• W3096498467 hasAuthorship W3096498467A5012932458 @default.
• W3096498467 hasAuthorship W3096498467A5016635620 @default.
• W3096498467 hasAuthorship W3096498467A5016773523 @default.
• W3096498467 hasAuthorship W3096498467A5017225753 @default.
• W3096498467 hasAuthorship W3096498467A5018098518 @default.
• W3096498467 hasAuthorship W3096498467A5021490305 @default.
• W3096498467 hasAuthorship W3096498467A5023947480 @default.
• W3096498467 hasAuthorship W3096498467A5025528565 @default.
• W3096498467 hasAuthorship W3096498467A5027358264 @default.
• W3096498467 hasAuthorship W3096498467A5028199476 @default.
• W3096498467 hasAuthorship W3096498467A5030071814 @default.
• W3096498467 hasAuthorship W3096498467A5030156947 @default.
• W3096498467 hasAuthorship W3096498467A5033227605 @default.
• W3096498467 hasAuthorship W3096498467A5037944783 @default.
• W3096498467 hasAuthorship W3096498467A5041966654 @default.
• W3096498467 hasAuthorship W3096498467A5043879976 @default.
• W3096498467 hasAuthorship W3096498467A5044088234 @default.
• W3096498467 hasAuthorship W3096498467A5046914814 @default.
• W3096498467 hasAuthorship W3096498467A5046965677 @default.
• W3096498467 hasAuthorship W3096498467A5047829491 @default.
• W3096498467 hasAuthorship W3096498467A5050727941 @default.
• W3096498467 hasAuthorship W3096498467A5052993212 @default.
• W3096498467 hasAuthorship W3096498467A5053254720 @default.
• W3096498467 hasAuthorship W3096498467A5053685451 @default.
• W3096498467 hasAuthorship W3096498467A5056151840 @default.
• W3096498467 hasAuthorship W3096498467A5063296742 @default.
• W3096498467 hasAuthorship W3096498467A5063417364 @default.
• W3096498467 hasAuthorship W3096498467A5063825892 @default.
• W3096498467 hasAuthorship W3096498467A5067177016 @default.
• W3096498467 hasAuthorship W3096498467A5069133916 @default.
• W3096498467 hasAuthorship W3096498467A5075950572 @default.
• W3096498467 hasAuthorship W3096498467A5076095056 @default.
• W3096498467 hasAuthorship W3096498467A5082287365 @default.
• W3096498467 hasAuthorship W3096498467A5083230780 @default.
• W3096498467 hasAuthorship W3096498467A5086066293 @default.
• W3096498467 hasAuthorship W3096498467A5089534178 @default.
• W3096498467 hasAuthorship W3096498467A5090912200 @default.
• W3096498467 hasBestOaLocation W30964984671 @default.

• next